… and Fleming and in two comparisons with placebo according to Bonferroni's method… venous
thromboembolism of 15 percent in the placebo group and 6 percent in one of the enoxaparin …

… comparing enoxaparin with placebo after major knee surgery [8]. In our earlier study, distal
… distal deep venous thrombosis with no proximal venous thrombosis in enoxaparin recipients. …

… A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in
acutely ill medical patients. N Engl J Med 1999;341:793–800. 12 Oster G, Tuden RL, Colditz …

… If we limit the comparison to examining similar events, the overall risk in PREVENT … vein
thrombosis occurred in 4.9% of MEDENOX placebo patients and 3.7% of PREVENT placebo …

… This decision was based on a meta-analysis showing that both regimens of the drug are
effective in reducing the risk of venous thromboembolism compared with placebo or no …

… in individual groups of patients with acute medical illnesses. Our post-hoc analysis shows
that enoxaparin was significantly superior to placebo in preventing VTE in patients who are …

… 40 mg of enoxaparin daily for 6 to 14 days over placebo on the … deep vein thrombosis or
nonfatal or fatal pulmonary embolism … a placebo-controlled trial evaluating 40 mg of enoxaparin …

… a placebo in the European Cooperative Acute Stroke studies (26, 27), which suggests that
both enoxaparin … with enoxaparin) was not unexpected because placebo-controlled studies in …

… patients given placebo, a relative risk reduction of 46.7% (95% confidence interval 7.7% to
69.3%). Symptomatic venous thromboembolism occurred in five patients in the placebo group …

… the relative risk of venous thromboembolism compared with placebo, but that … comparing
enoxaparin with unfractionated heparin, similar efficacy in preventing venous thromboembolism …